<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571100</url>
  </required_header>
  <id_info>
    <org_study_id>18-692E</org_study_id>
    <nct_id>NCT03571100</nct_id>
  </id_info>
  <brief_title>Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections</brief_title>
  <official_title>Patient Comfort and Antimicrobial Efficacy With Aqueous Chlorhexidine Versus Povidine-Iodine (Betadine) as Ocular Surface Disinfectant Prior to Intravitreal Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MidAtlantic Retina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective interventional study is to compare patient experience, ocular
      surface irritation, and bacterial colony counts and microbial spectrum between povidine
      iodine and aqueous chlorhexidine as ocular surface antiseptic prior to intravitreal injection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center prospective study comparing antiseptic efficacy and ocular surface
      irritation with PI (povidine iodine) and AC (aqueous chlorhexidine). Patients will be
      recruited in the clinical offices of the Retina Service of Wills and Hospital/Mid Atlantic
      Retina clinic offices. Patients who are determined to require bilateral intravitreal
      injections of an anti-VEGF (vascular endothelial growth factor) agents by a retina specialist
      at their regularly scheduled retina appointment will be evaluated for qualification by study
      personnel. Patients who meet inclusion criteria will be identified and informed consent will
      be obtained. Prior to injection, topical anesthetic (0.5% proparacaine, Alcon) will be
      instilled in both eyes. Study personnel will obtain four samples from the superior and
      inferior fornices of the upper and lower lids of both eyes using swabs (COPAN ESwab,
      ThermoFisher Scientific) for patients enrolled at Wills. Topical antisepsis will then be
      applied, the first eye will be randomized to one drop of either PI 5% or AC 0.1% and the
      second eye will receive the other agent. One minute after instillation of the eye drop to
      each eye, patients will rate their pain in each eye using the Wong-Baker (smiley face) rating
      scale. The injections will then be performed by the treating retina specialist. Following the
      injection, a second conjunctival culture will be taken in an identical manner to the first
      for patients enrolled at Wills. Study personnel will then instill fluorescein dye
      (fluorescein sodium ophthalmic, BioGlo) into each eye, and a brief slit lamp examination will
      be performed. Study personnel will record surface findings according to the Ocular Surface
      Score and a numerical score for each eye will be determined. On post-injection day one study
      personnel will call the patient and ask to rate the pain in each eye using the same verbal
      numerical rating scale. No additional clinic visits will be required as part of the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">May 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized prospective trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The participant will be masked to which drug they receive, the investigator performing the analysis will also be masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Comfort</measure>
    <time_frame>One day following injection</time_frame>
    <description>Patient Comfort using the Wong Baker FACES Pain Scale [Scale: 0(No pain) - 10 (Worst Pain)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Culture of conjunctiva for bacteria</measure>
    <time_frame>7 days</time_frame>
    <description>Microbial flora</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Comfort</measure>
    <time_frame>I minute after drop instilled</time_frame>
    <description>Patient Comfort using the Wong Baker FACES Pain Scale [Scale: 0(No pain) - 10 (Worst Pain)]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Diabetic Vascular Diseases</condition>
  <condition>Proliferative Retinopathy</condition>
  <condition>Retina Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Povidine-Iodine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorhexidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine</intervention_name>
    <description>Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)</description>
    <arm_group_label>Chlorhexidine</arm_group_label>
    <other_name>Aqueous chlorhexidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidine-Iodine</intervention_name>
    <description>Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)</description>
    <arm_group_label>Povidine-Iodine</arm_group_label>
    <other_name>Betadine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current patient of the Wills Eye Hospital Retina Service including all Mid Atlantic
             Retina offices

          -  Clinical indication of bilateral intravitreal injection as determined by the treating
             retina specialist for a diagnosis of age-related macular degeneration, diabetic
             macular edema, proliferative retinopathy or macular edema associated with retina vein
             occlusion.

          -  Age greater than 18.

        Exclusion Criteria:

          -  Documented allergy to PI or AC

          -  Current diagnosis of infectious keratitis

          -  History of unilateral contact lens wear in the past 30 days

          -  Current unilateral use of prescription eye drops.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunir Garg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MidAtlantic Retina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Formoso</last_name>
    <phone>215-928-3092</phone>
    <email>research@midatlanticretina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Devida Long</last_name>
    <phone>215-928-3092</phone>
    <email>research@midatlanticretina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MidAtlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Formoso</last_name>
      <phone>215-928-3092</phone>
      <email>research@midatlanticretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Devida Long</last_name>
      <phone>215-928-3092</phone>
      <email>research@midatlanticretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sunir Garg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>MidAtlantic Retina</investigator_full_name>
    <investigator_title>Dr Sunir Garg MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Diabetic Angiopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

